New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 11, 2014
14:56 EDTCEMPCempra to present data on solithromycin at ECCMID
Cempra announced that it will present data at the European Congress of Clinical Microbiology and Infectious Diseases, ECCMID, in Barcelona, Spain, that continue to enhance the profile of solithromycin in regards to potential new indications, safety and spectrum of activity particularly against contemporary strains. Presentations will occur on Saturday, May 10 to Tuesday, May 13.Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra said, "We continue to collect exciting data on the emerging profile of solithromycin, our fourth-generation macrolide. The data presented at this year's ECCMID are excellent examples of that trend. Proof of concept in otitis media was presented and this adds to the broadening use potential of solithromycin that includes pediatric use, infections in pregnancy, gonorrhea and non-infectious diseases such as COPD and NASH among others. We also presented the full hepatic insufficiency study that we announced in 3Q13, which demonstrated the benign tolerability profile seen to date. The emerging safety profile is promising based on this study as well as the safety profile seen in our Phase 2 CABP trial and the lack of a QT effect in our Thorough QT study."
News For CEMP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 5, 2016
12:12 EDTCEMPOn The Fly: Top stock stories at midday
Stocks began the day lower and have seen little in the way of buying since the open. As the market digested the monthly jobs data and watched the price of oil turn negative, the selling that had taken a two day break was renewed. The Nasdaq is the biggest loser, falling over 2%, while the Dow is down about 1%. ECONOMIC EVENTS: In the U.S., nonfarm payrolls rose 151,000 in January, versus expectations for an increase of 190,000. The unemployment rate fell to 4.9%, versus expectations for it to stay at 5.0%. Average hourly earnings climbed 0.5% month-over-month, versus the consensus forecast for them to rise 0.3%. The trade deficit widened 2.7% to $43.4B in December, as exports dipped 0.3% and imports rose 0.3%. A report on Consumer Credit growth in December is due out at 3 pm ET. COMPANY NEWS: The shares of LinkedIn (LNKD) plunged 40% after the professional network reported stronger than expected fourth quarter results, but its 2016 guidance came in significantly below expectations. At least nine Wall Street research firms responded to the guidance miss by downgrading the stock... Also tumbling in the wake of its quarterly report was "Big Data" software provider Tableau (DATA), which fell 47% after its full-year guidance came in significantly below expectations. Tableau blamed its guidance miss on weaker IT spending trends, as well as competition, and a number of other companies that sell software to businesses also fell following its report, including peer Splunk (SPLK), NetSuite (N), Salesforce (CRM) and Workday (WDAY). MAJOR MOVERS: Among the notable gainers was Cempra (CEMP), which gained about 5% after it said that its solithromycin drug met primary and secondary objectives in its Phase 3 study. Also higher were Tyson Foods (TSN) and Post Holdings (POST), which gained 10% and 11.5%, respectively, after reporting quarterly earnings. Among the noteworthy losers was Vertex (VRTX), which fell 5% after the FDA said that it cannot currently approve a label expansion for Kalydeco in children with residual function mutations. Also lower were Lion's Gate (LGF), YRC Worldwide (YRCW), and Redbox-parent Outerwall (OUTR), which were down 33%, 30%, and 17%, respectively, after reporting quarterly earnings. INDEXES: Near midday, the Dow was down 171.21, or 1.04%, to 16,245.37, the Nasdaq was down 110.39, or 2.45%, to 4,399.17, and the S&P 500 was down 27.10, or 1.41%, to 1,888.35.
07:05 EDTCEMPCempra says solithromycin met primary, secondary objectives in Phase 3 study
Subscribe for More Information
February 1, 2016
08:51 EDTCEMPCempra should be bought at current levels, says Janney Capital
Subscribe for More Information
07:37 EDTCEMPCempra and Macrolide sign agreement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use